-
细胞凋亡又称细胞程序性死亡,即细胞在一定生理及病理条件下,通过一系列基因的激活、表达、调控,按照自身程序出现的主动性、生理性的死亡过程[1]。通过放化疗等手段诱导肿瘤细胞凋亡是各种抗肿瘤治疗的主要机制之一,而且细胞凋亡往往发生在肿瘤细胞死亡的早期阶段。因此,可以通过检测细胞凋亡评价抗肿瘤药物的早期疗效。
近年来,细胞凋亡探针成为研究热点,尤其在肿瘤疗效监测方面受到更多关注。文献报道最多的细胞凋亡分子探针为99Tcm-膜联蛋白(Annexin V),但是该探针特异性差,不能区分细胞凋亡和坏死,且相对分子质量大、药代动力学差[2-4],因此未能在临床得到推广。细胞凋亡的关键酶caspase-3在凋亡早期阶段被激活,可用于凋亡的早期评价。天冬氨酸-谷氨酸-缬氨酸-天冬氨酸(Asp-Glu-Val-Asp, DEVD)是caspase-3的作用底物,能特异性地被caspase-3裂解而滞留于凋亡细胞中,基于此原理,笔者初步合成了含DEVD链的多肽分子探针99TcmCP3-peptide,并研究其在凋亡模型体内外的生物学分布及SPECT静态显像的初步分析。
-
成功制备99Tcm-CP3-peptide,合成率为(64.5±5.2)%,产品为无色透明溶液,pH值为6.5~7.5。99Tcm-CP3-peptide标记率>99%,放射性出峰时间为5.74 min,室温放置0、1、2、4和6 h的放射化学纯度分别为(99.33±0.12)%、(99.30±0.38)%、(99.02±0.13)%、(97.54±0.12)%和(97.02±0.26)%。
-
紫杉醇诱导肺腺癌A549细胞凋亡后,用γ计数器测定细胞及上清液的放射性计数,其中化疗组Cin/Cout为10.27±2.02,对照组Cin/Cout为1.09±0.03,化疗组为对照组的7.3倍。肿瘤细胞凋亡检测结果见图1,由图1可知,化疗组细胞凋亡率为(75.62±2.57)%,对照组细胞凋亡率为(3.42±0.32)%,化疗组细胞凋亡率高于对照组,差异有统计学意义(t=6.97,P<0.05)。化疗组和对照组的 Cin/Cout与流式细胞仪检测的凋亡细胞百分比呈正相关,且差异有统计学意义(r=0.970,P<0.05)。
-
由表1可见,肾脏是99Tcm-CP3-peptide放射性浓聚最多的器官,注射后15 min达到峰值,为(8.95±0.51)%ID/g,2 h为(2.25±0.78 )%ID/g,清除较快;血液中放射性清除速度很快,到2 h即下降到(2.25±0.24)%ID/g;肿瘤组织在注射后1 h放射性摄取值达到峰值(4.26±1.03)%ID/g;心脏、脾脏、肺等重要器官放射性摄取值均较低;但在肝脏中摄取稍高:5 min时为(3.21±0.75)%ID/g,到1 h时降为(2.81±0.72)%ID/g,下降速度较慢。
组织或器官 注射后时间 5 min 15 min 30 min 60 min 120 min 240 min 血液 10.51±3.21 9.50±2.71 6.34±1.24 4.25±1.02 2.25±0.24 2.65±1.31 心脏 1.27±1.21 1.35±1.51 1.02±0.85 0.86±0.95 0.68±0.65 0.45±0.23 肝脏 3.21±0.75 3.33±1.41 2.54±0.54 2.81±0.72 1.85±0.54 1.24±0.32 脾脏 2.91±1.21 2.11±0.35 1.56±0.35 0.86±0.30 0.54±0.25 0.15±0.24 肾脏 4.85±1.20 8.95±0.51 6.34±1.26 4.22±0.42 2.25±0.78 1.84±0.31 肺 2.67±1.01 2.31±0.85 1.85±0.62 1.32±0.21 1.15±0.78 0.65±0.33 小肠 1.13±0.22 1.24±0.21 1.08±0.35 0.75±0.32 0.54±0.51 0.24±0.05 肌肉 1.31±1.20 1.52±0.89 1.27±0.81 1.08±0.63 0.68±0.31 0.47±0.21 骨骼 1.69±1.24 2.21±1.61 1.78±0.84 1.23±0.86 0.86±1.10 0.57±0.34 肿瘤 2.75±0.31 3.21±1.03 3.73±0.84 4.26±1.03 3.21±0.96 1.30±0.56 表 1 不同时间99Tcm-CP3-peptide在肺腺瘤A549细胞荷瘤裸鼠体内的生物学分布(
$ \bar x \pm s$ Table 1. Biological distribution of 99Tcm-CP3-peptide in nude mice with tumor at different time points (
$ \bar x \pm s$ -
图2显示,注射99Tcm-CP3-peptide后1 h即可获得清晰图像,化疗组(图2中A)肿瘤部位有明显放射性摄取,对照组(图2中B)肿瘤部位仅有少量放射性摄取。化疗组T/NT为3.83±0.11,显著高于对照组(1.57±0.09),且差异有统计学意义(t=16.19,P<0.05)。
-
光镜下,肿瘤组织苏木精-伊红染色示化疗组肿瘤组织(图3中A)见大量核固缩(细胞核体积减小,嗜碱性增强)、核碎裂(核膜破裂,细胞核碎裂)及凋亡细胞(细胞体积缩小,胞质致密,嗜酸性增强);对照组(图3中B)仅见少量核固缩、核碎裂及少量凋亡细胞。
新型细胞凋亡分子探针 99Tcm-CP3-peptide的制备及在肺腺癌细胞系体内外的实验研究
Preparation of 99Tcm-CP3-peptide and in vitro and in vivo study of lung adenocarcinoma cell lines
-
摘要:
目的 制备含天冬氨酸-谷氨酸-缬氨酸-天冬氨酸(DEVD)核心的多肽细胞凋亡分子探针99Tcm-CP3-peptide,研究其在肺腺癌细胞系A549化疗后体内外的生物学分布及SPECT显像。 方法 采用双功能螯合法合成99Tcm-CP3-peptide,分别于标记后0、1、2、4、6 h行高效液相色谱(HPLC)法检测放射性化学纯度。对经紫杉醇化疗的肺腺癌A549细胞进行体外细胞结合实验,对照组未经化疗,测量细胞内外放射性比值(Cin/Cout),并用流式细胞仪检测细胞凋亡率。经紫杉醇化疗的荷瘤裸鼠尾静脉注射99Tcm-CP3-peptide 3.7 MBq,分别于5、15、30、60、120、240 min测其生物学分布,并行SPECT静态显像,勾画感兴趣区(ROI),计算肿瘤/对侧正常肌肉组织的比值(T/NT)。取显像后的肿瘤组织进行苏木精-伊红染色,观察肿瘤组织的形态学变化。两组比较采用t检验,相关性研究采用双变量相关分析。 结果 99Tcm-CP3-peptide在0、1、2、4和6 h的放射化学纯度均>97%,合成率为(64.5±5.2)%。体外细胞结合实验结果表明,经紫杉醇化疗后24h,肿瘤细胞Cin/Cout为10.27±2.02,对照组Cin/Cout为1.09±0.03,化疗组为对照组的7.3倍。对同状态的肿瘤细胞行流式细胞检测,化疗组细胞凋亡率为(75.62±2.57)%,对照组细胞凋亡率为(3.42±0.32)%,化疗组和对照组Cin/Cout与流式细胞仪检测的凋亡细胞百分比呈明显正相关(r=0.970,P<0.05)。荷瘤裸鼠体内分布实验结果显示,99Tcm-CP3-peptide在血液中清除速度较快,且主要经肾脏代谢;心脏、脾脏、肺等重要器官放射性摄取值均较低;但在肝脏中摄取稍高且代谢速度较慢;肿瘤组织摄取值在注射后1 h达到峰值[(4.26±1.03)%ID/g]。荷瘤小鼠给药后1 h即可获得清晰图像,勾画ROI显示:化疗组T/NT为3.83±0.11,显著高于对照组的1.57±0.09,两者间差异有统计学意义(t=16.19, P<0.05)。病理结果显示化疗组肿瘤组织见大量核固缩、核碎裂及凋亡细胞;对照组仅见少量核固缩、核碎裂及少量凋亡细胞。 结论 99Tcm-CP3-peptide是一种靶向caspase-3的显像剂,具有较好的生物学分布,可应用于动物模型肿瘤组织凋亡显像,在监测化疗后肿瘤细胞凋亡方面有一定的临床潜在价值。 -
关键词:
- 同位素标记 /
- 肽类 /
- 细胞凋亡 /
- 体层摄影术,发射型计算机,单光子 /
- 肿瘤
Abstract:Objective To preparation a99Tcm labeled caspase -3 polypeptide apoptosis molecular probe(99Tcm-CP3-peptide) based on aspartic glutamic acid-valine-aspartic acid(DEVD) as the core and study the biodistribution and SPECT imaging of lung adenocarcinoma cell line(A549) after chemotherapy. Methods 99Tcm-cp3-peptide was synthesized by bifunctional chelate method, and the radiochemical purity was detected by HPLC at the time points of 0, 1, 2, 4, 6 hours after the labeling. An in vitro binding assay was performed in A549 cells treated with paclitaxel.In the control group, without chemotherapy, the intracellular and extracellular radioactive ratio(Cin/Cout) was measured, and the cell apoptosis rate was detected by flow cytometry. 99Tcm-CP3-peptide was injected via tail vein of tumor bearing nude mice treated with paclitaxel(3.7 MBq for each mouse), to detect the biological distribution of 5, 15, 30, 60, 120, 240 min respectively. Static SPECT imaging was performed, ROI outlined, and the ratio of tumor/contralateral normal muscle tissue was calculated. HE staining was performed to observe the morphological changes of tumor tissues after imaging. Test was used for comparison between the two groups, and bivariate correlation analysis was used for correlation study, P<0.05 was considered statistically significant. Results The radiochemical purity of 99Tcm-CP3-peptide at 0, 1, 2, 4 and 6 h was greater than 97%. The synthesis rate was(64.5+5.2)%. An in vitro investigation showed that the Cin/Cout in the tumor cell chemotherapy group was 10.27±2.02 vs. 1.09±0.03 in control group 24 h after paclitaxel chemotherapy. The chemotherapy group of Cin/Cout was 7.3 times as high as that of the control group. Flow cytometric detection of tumor cells in the same state, the rate of apoptosis in the chemotherapy group was(75.62±2.57)% vs.(3.42±0.32)% in contorl group. The ratio of Cin/Cout in the chemotherapy group and the control group was positively correlated with the percentage of apoptotic cells detected by flow cytometry(r=0.970, P<0.05). Invivo distribution of tumor bearing mice showed that: 99Tcm-CP3-peptide is rater fast in blood clearance, and mainly metabolized through kidney. The values of radioactive uptake were low for important organs such as heart, spleen and lung etal, but it is slightly higher in the liver and slower in metabolism. The value of tumor tissue uptake reached a peak(4.26±1.03)%ID/g after injection of 1 h. Clear images of the tumor bearing mice can be obtained 1h after injection of drugs. The ROI showed that the ratio of T/NT in the chemotherapy group was 3.83±0.11, which was significantly higher than that of the control group(1.57±0.09, t=16.19, P<0.05). After imaging, HE staining of tumor tissue showed that a large number of nuclear retraction, nuclear fragmentation and apoptotic cells were found in the tumor tis-sue of the chemotherapy group and only a small amount of that were in control group. Conclusions 99Tcm-CP3-peptide, a kind of imaging agent targeting caspase-3 activity,which has good biological distribution, and can be applied to apoptosis imaging of animal models, it has a potential clinical value in monitoring tumor cell apoptosis after chemotherapy. -
Key words:
- Isotope labeling /
- Peptides /
- Apoptosis /
- Tomography, emission-computed, single-photon /
- Tumor
-
表 1 不同时间99Tcm-CP3-peptide在肺腺瘤A549细胞荷瘤裸鼠体内的生物学分布(
$ \bar x \pm s$ Table 1. Biological distribution of 99Tcm-CP3-peptide in nude mice with tumor at different time points (
$ \bar x \pm s$ 组织或器官 注射后时间 5 min 15 min 30 min 60 min 120 min 240 min 血液 10.51±3.21 9.50±2.71 6.34±1.24 4.25±1.02 2.25±0.24 2.65±1.31 心脏 1.27±1.21 1.35±1.51 1.02±0.85 0.86±0.95 0.68±0.65 0.45±0.23 肝脏 3.21±0.75 3.33±1.41 2.54±0.54 2.81±0.72 1.85±0.54 1.24±0.32 脾脏 2.91±1.21 2.11±0.35 1.56±0.35 0.86±0.30 0.54±0.25 0.15±0.24 肾脏 4.85±1.20 8.95±0.51 6.34±1.26 4.22±0.42 2.25±0.78 1.84±0.31 肺 2.67±1.01 2.31±0.85 1.85±0.62 1.32±0.21 1.15±0.78 0.65±0.33 小肠 1.13±0.22 1.24±0.21 1.08±0.35 0.75±0.32 0.54±0.51 0.24±0.05 肌肉 1.31±1.20 1.52±0.89 1.27±0.81 1.08±0.63 0.68±0.31 0.47±0.21 骨骼 1.69±1.24 2.21±1.61 1.78±0.84 1.23±0.86 0.86±1.10 0.57±0.34 肿瘤 2.75±0.31 3.21±1.03 3.73±0.84 4.26±1.03 3.21±0.96 1.30±0.56 -
[1] Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biologi-cal phenomenon with wide-ranging implications in tissuekenetics[J]. Br J Cancer, 1972, 26(4): 239−257. DOI: 10.1038/bjc.1972.33 [2] 黄代娟, 兰晓莉, 张永学, 等. 99Tcm-HYNIC-Annexin V动脉粥样硬化显像的实验研究[J]. 中华核医学杂志, 2008, 28(3): 206−208. DOI: 10.3760/cma.j.issn.2095−2848.2008.03.020
Huang DJ, Lan XL, Zhang YX, et al. Research on the 99Tcm-HYNICAnnexin V scintigraphy of rabbit atherosclerotic lesions[J]. Chin J Nucl Med, 2008, 28(3): 206−208. DOI: 10.3760/cma.j.issn.2095−2848.2008.03.020[3] 郑玉民, 王自正, 颜珏, 等. 99Tcm-His10-Annexin吁探测非小细胞肺癌细胞凋亡的实验研究[J]. 中华核医学杂志, 2008, 28(6): 378−382. DOI: 10.3760/cma.j.issn.2095−2848.2008.06.006
Zheng YM, Wang ZZ, Yan J, et al. In vivo detection of non-small cell lung cancer apoptosis with 99Tcm-His10-Annexin吁[J]. Chin J Nucl Med, 2008, 28(6): 378−382. DOI: 10.3760/cma.j.issn.2095−2848.2008.06.006[4] Reshef A, Shirvan A, Akselrod-Ballin A, et al. Small-moleculebiom arkers for clinica PET imaging of apoptosis[J]. J Nucl Med, 2010, 51(6): 837−840. DOI: 10.2967/jnumed.109.063917 [5] Falschlehner C, Boutros M. Innate immunity: regulation of caspases by IAP-dependent ubiquitylation[J]. EMBO J, 2012, 31(12): 2750−2752. DOI: 10.1038/emboj.2012.148 [6] Zhang Y, Goodyer C, LeBlanc A. Selective and protracted apoptosis in human primary neurons microinjected with active caspase-3, -6, -7, and -8[J]. J Neurosci, 2000, 20(22): 8384−8389. DOI: 10.1523/JNEUROSCI.20−22−08384.2000 [7] Belhocine T, Steinmetz N, Hustinx R, et al. Increased uptake of the apoptosis-imaging agent 99Tcm recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis[J]. Clin Cancer Res, 2002, 8(9): 2766−2774. [8] van de Wiele C, Lahorte C, Vermeersch H, et al. Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography[J]. J Clin Oncol, 2003, 21(18): 3483−3487. DOI: 10.1200/JCO.2003.12.096 [9] Kartachova M, Haas RL, Olmos RA, et al. In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response[J]. Radiother Oncol, 2004, 72(3): 333−339. DOI: 10.1016/j.radonc.2004.07.008 [10] Haas RL, de Jong D, Valdés ORA, et al. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients[J]. Int J Radiat Oncol Biol Phys, 2004, 59(3): 782−787. DOI: 10.1016/j.ijrobp.2003.11.017 [11] 张宝石, 周乃康, 王卉, 等. 18F-FP-peptide用于化疗后肿瘤细胞凋亡显像[J]. 中华核医学与分子影像杂志, 2012, 32(2): 84−89. DOI: 10.3760/cma.j.issn.2095−2848.2012.02.002
Zhang BS, Zhou NK, Wang H, et al. Imaging of apoptosis with 18F-FP-peptide focused on the evaluation of tumor response to chemotherapy[J]. Chin J Nucl Med Mol Imaging, 2012, 32(2): 84−89. DOI: 10.3760/cma.j.issn.2095−2848.2012.02.002[12] Xia CF, Chen G, Gangadharmath U, et al. In vitro and in vivo evaluation of the caspase-3 substrate-based radiotracer[18F]-CP18 for PET imaging of apoptosis in tumors[J]. Mol Imaging Biol, 2013, 15(6): 748−757. DOI: 10.1007/s11307−013−0646−7 [13] Shen B, Jeon J, Palner M, et al. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-triggered nanoaggregation probe[J]. Angew Chem Int Ed Engl, 2013, 52(40): 10511−10514. DOI: 10.1002/anie.201303422 [14] Palner M, Shen B, Jeon J, et al. Preclinical Kinetic Analysis of the Caspase-3/7 PET Tracer 18F-C-SNAT: Quantifying the Changes in Blood Flow and Tumor Retention After Chemotherapy[J]. J Nucl Med, 2015, 56(9): 1415−1421. DOI: 10.2967/jnumed.115.155259 [15] Witney TH, Hoehne A, Reeves RE, et al. A Systematic Comparison of 18F-C-SNAT to Established Radiotracer Imaging Agents for the Detection of Tumor Response to Treatment[J]. Clin Cancer Res, 2015, 21(17): 3896−3905. DOI: 10.1158/1078−0432.CCR−14−3176